GLP-1 receptor agonists represent a major advance in obesity pharmacotherapy — but like all prescription medications, they are not appropriate for every patient. Understanding contraindications is not just a regulatory formality: it is the clinical foundation that separates safe, effective therapy from preventable harm. This guide covers who should not take GLP-1 medications, who requires special caution, and what every patient should discuss with their physician before starting.
This guide is for informational purposes only. Contraindication determinations must be made by a licensed physician who reviews your complete medical history. Do not self-determine eligibility based on this article alone.
Absolute Contraindications — These Patients Should Not Take GLP-1 Medications
The following are absolute contraindications to semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) based on FDA-approved prescribing information:
- Personal or family history of medullary thyroid carcinoma (MTC): In rodent studies, GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors. Human relevance has not been established, but the FDA mandates a black box warning and contraindication for all patients with personal or family history of MTC.
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2): MEN2 is associated with MTC risk. GLP-1 receptor agonists are absolutely contraindicated in this population.
- Known serious hypersensitivity to semaglutide or tirzepatide: Anaphylaxis and angioedema have been reported. Prior serious allergic reaction to these agents or any component of the formulation is a contraindication.
- Pregnancy: GLP-1 receptor agonists have not been adequately studied in human pregnancy. Animal studies suggest potential fetal harm. Women who are pregnant should not take these medications; women of childbearing potential should use reliable contraception during treatment and for a defined period after discontinuation (consult prescribing information for specific intervals).
Find a GLP-1 option matched to your state and budget in 60 seconds.
Get My Match →Relative Contraindications — These Patients Require Careful Clinical Evaluation
The following conditions are not absolute contraindications but require individualized clinical assessment before initiating GLP-1 therapy:
- History of pancreatitis: GLP-1 receptor agonists have been associated with acute pancreatitis in post-marketing reports. The FDA prescribing information includes pancreatitis as a warning. Patients with prior acute or chronic pancreatitis require careful risk-benefit assessment. If pancreatitis is suspected during therapy, discontinue immediately.
- Diabetic retinopathy in patients with type 2 diabetes: Rapid improvement in glycemic control with GLP-1 therapy has been associated with worsening of diabetic retinopathy in some patients. The SUSTAIN-6 trial reported a higher rate of retinopathy complications in the semaglutide group.1 Ophthalmologic assessment before initiating therapy is advisable in patients with known retinopathy.
- Gastroparesis or significant gastric motility disorders: GLP-1 medications substantially slow gastric emptying. In patients with pre-existing gastroparesis, this effect can worsen symptoms significantly. This is a clinical judgment call — not automatic exclusion, but requires careful monitoring.
- Gallbladder disease: GLP-1 therapy is associated with increased rates of cholelithiasis (gallstones). Patients with known gallbladder disease or prior cholecystectomy complications should be monitored. The STEP trials reported higher rates of gallbladder disease in the semaglutide groups.
- Eating disorders: GLP-1 therapy in patients with restrictive eating disorders (anorexia nervosa, ARFID) requires careful clinical framing and psychiatric co-management. The appetite suppression effects can exacerbate restrictive behaviors in vulnerable patients.
- Heart rate: GLP-1 medications increase resting heart rate by approximately 2–4 bpm on average. In patients with tachyarrhythmias, this should be monitored and discussed with a cardiologist if significant.
- Severe renal impairment: GLP-1 medications can cause GI fluid losses (nausea, vomiting, diarrhea) that precipitate acute kidney injury in patients with pre-existing renal insufficiency. Hydration monitoring is important in this population.
Drug Interactions to Discuss With Your Physician
GLP-1 medications slow gastric emptying, which can affect the absorption rate and timing of oral medications taken concomitantly. Important interactions include:
- Oral medications with narrow therapeutic windows (warfarin, cyclosporine, certain antibiotics) — absorption timing may change
- Oral contraceptives — absorption may be affected; additional non-oral contraception may be advised
- Insulin and insulin secretagogues — hypoglycemia risk increases; dose reduction of insulin or sulfonylureas is typically required
- Oral diabetes medications — glycemic targets and medication doses may need adjustment with GLP-1 initiation
What This Means for You
If you have any of the above conditions, that does not automatically mean GLP-1 therapy is unavailable to you — it means a thorough clinical conversation with a licensed physician is essential before starting. Legitimate telehealth programs require a complete health intake precisely to identify these factors.
To see verified programs that conduct thorough medical intake before prescribing, use our matching tool — filtered to your state and budget.